Phibro Animal Health Corporation

NASDAQ:PAHC

Drug Manufacturers - Specialty & Generic

Healthcare
$35.57 +1.23%

+$0.38 today

Market cap
$1.44B
Beta
0.46
P/E (TTM)
13.3
EPS (TTM)
$2.35
Dividend yield
1.54%
52W Low $23.57High $60.08

Volume 0.11M

Average 0.37M

PAHC Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Phibro Animal Health CorporationNASDAQ: PAHC

Net Margin · Q3 FY2026 · quarter ended Mar 2026

Net margin holds steady near 6.3%

Net margin was 6.3% in Q3 FY2026, up 0.3 pp from a year earlier. On a trailing-twelve-month basis it was 6.3%, up 3.7 pp year over year. Over 3 fiscal years it narrowed by 1.5 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 4 analysts of 8.4% for the fiscal year ending Jun 2026, up from 3.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
6.3%-1.1 pp QoQ
Last fiscal yearJun 2025
3.7%+3.5 pp YoY
LTMMar 2026
6.3%+3.7 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.3 pp+3.1 pp+2.9 pp
1 year+3.5 pp+4.7 pp+1.2 pp
3 years-1.5 pp+6.0 pp+7.5 pp
5 years+7.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
3.7%
Year-over-year change
+3.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How PAHC compares with its peers on the latest reported figures

  • PAHC's LTM Mar 2026 net margin of 6.3% is the 2nd highest of the 6 companies compared; the peer median is -2.9%.
  • Its year-over-year change of +3.7 pp is the 2nd highest of 6, against a peer median of -3.6 pp.
  • Over three fiscal years its change of -1.5 pp compares with a peer median of +1.9 pp.
PAHC Competitors Peer median
Net Margin for PAHC and competitors
Company Period LTM level YoY 3-year change
ZTSZoetis Inc.LTM Jun 202627.5% -0.3 pp+2.1 pp
PAHCPhibro Animal Health CorporationLTM Mar 20266.3% +3.7 pp-1.5 pp
MRKMerck & Co., Inc.LTM Jun 20264.8% -21.0 pp+3.6 pp
ELANElanco Animal Health IncorporatedLTM Sep 2026-2.9% -3.6 pp-3.2 pp
NEOGNeogen CorporationLTM Aug 2026-6.3% +111.3 pp+1.9 pp
ZYBTZhengye Biotechnology Holding LimitedFY2025-60.0% -66.0 pp-77.9 pp
Peer median (excluding PAHC) -2.9%-3.6 pp+1.9 pp

Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue833.35M942.26M977.89M1.02B1.3B
Cost of Revenue561.97M656.86M679.65M704.59M896.27M
Gross Profit271.38M285.4M298.24M313.09M399.94M
Gross Margin32.6%30.3%30.5%30.8%30.9%
Research & Development00000
Selling, General & Admin196.51M206.41M226.39M259.78M289.48M
Operating Expenses196.51M206.41M226.39M259.78M289.48M
Depreciation & Amortization31.88M32.71M34.01M36.18M45.61M
EBITDA110.21M117.13M106.03M69.06M146.85M
EBITDA Margin13.2%12.4%10.8%6.8%11.3%
Operating Income74.87M78.99M71.85M53.32M110.47M
Operating Margin9.0%8.4%7.3%5.2%8.5%
Interest Income838K816K3.36M4.47M2.62M
Interest Expense10.4M12.1M17.95M21.97M33.25M
Other Income / Expenses(8.4M)(6.66M)(17.78M)(42.4M)(42.47M)
Income Before Tax66.47M72.33M54.07M10.92M67.99M
Pre-Tax Margin8.0%7.7%5.5%1.1%5.2%
Income Tax Expense12.08M23.15M21.47M8.5M19.73M
Net Income54.39M49.18M32.61M2.42M48.26M
Net Margin6.5%5.2%3.3%0.2%3.7%
EPS (Basic)1.341.210.810.061.19
EPS (Diluted)1.341.210.810.061.19
Weighted Avg Shares40.5M40.5M40.5M40.5M40.5M
Weighted Avg Shares (Diluted)40.5M40.5M40.5M40.52M40.7M

Phibro Animal Health Corporation

NASDAQ:PAHC

Intrinsic Alpha fair value

Locked

Current Price

$35.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.